Comparing Clinical Outcomes of Tiotropium/Olodaterol, Umeclidinium/Vilanterol, and Indacaterol/Glycopyrronium Fixed-Dose Combination Therapy in Patients with Chronic Obstructive Pulmonary Disease in Taiwan: A Multicenter Cohort Study.

Int J Chron Obstruct Pulmon Dis · 2022 · PMC9058003 · PMID 35510163

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a decreasing trendno p-value reported

Regarding the lung function, a decreasing trend in FEV 1 was found in Tio/Olo but not in Umec/Vi or Ind/Gly, with similar trends detected in FVC at 12 months ( Table 4 ).

also in 47,180 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.